N-(4-bromobenzylidene)-2,3-dihydrobenzo[b][1,4]dioxin-6-amine: Synthesis, crystal structure, docking and in-vitro inhibition of PLA2

• Published in: Journal of molecular structure Vol. 1218; p. 128441
• Main Authors: Hema, M.K., ArunRenganathan, R.R., Nanjundaswamy, S., Karthik, C.S., Mohammed, Yasser Hussein Issa, Alghamdi, Saad, Lokanath, N.K., Ravishankar Rai, V., Nagashree, S., Mallu, P.
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 15.10.2020
• Subjects: 4-Bromobenzaldehyde; Anti-inflammatory activity; Docking; PLA2; Schiff base; Schiff base; PLA2; Docking; Anti-inflammatory activity; 4-Bromobenzaldehyde
• ISSN: 0022-2860; 1872-8014
• DOI: 10.1016/j.molstruc.2020.128441

The novel N-(4-bromobenzylidene)-2,3-dihydrobenzo[b][1,4]dioxin-6-amine compound is designed and subjected to structural studies, inhibition of sPLA2, and molecular docking. The compound was synthesized by condensation of 1,4-benzodioxan-6-amine and 4-bromobenzaldehyde and characterized by various spectral techniques. Single crystal X-ray diffraction analysis confirmed the 3D molecular structure and established the different intermolecular interactions responsible for the crystal structure stability. Further synthesized compound was evaluated for anti-inflammatory activity using sPLA2 inhibition by indirect hemolytic assay. The compound showed good inhibition against sPLA2 enzyme compared with standard diclofenac, which is validated by molecular docking with a −7.60 kcal/mol docking score. •The novel N-(4-bromobenzylidene)-2,3-dihydrobenzo[b][1,4]dioxin-6-amine compound is synthesized.•The synthesized compound was characterized by various spectral techniques.•Single crystal X-ray diffraction analysis confirmed the 3D molecular structure.•The synthesized compound showed good inhibition against sPLA2 enzyme and validated with docking score −7.6 kcal/mol.